Palenie tytoniu jest udowodnioną przyczyną wielu nowotworów i odpowiada za około 1/3 ogółu zgonów nowotworowych. O ile niekorzystne skutki używania tytoniu są dobrze znane, nie docenia się szkód wynikających z […] Read more
Tobacco use is a well-established cause of cancer, contributing to about 1 in 3 cancer deaths annually. Whereas detrimental effects of smoking are well recognized, the harms of continued smoking […] Read more
The US National Cancer Institute (NCI), a division of the US National institutes of Health (NIH), is partnering with Cancer Research UK, the world’s largest independent cancer research charity, to […] Read more
The US Food and Drug Administration (FDA) granted Accelerated Approval to pralsetinib as treatment for adults with metastatic NSCLC who harbor RET fusions. The first and only test to identify RET fusion–positive NSCLC, the Oncomine Dx Target […] Read more
August 2020 was a groundbreaking month for liquid biopsy technology, with two assays approved by the US Food and Drug Administration (FDA) as companion diagnostics just weeks apart. The Guardant360 CDx assay, approved August 7, was […] Read more
A Decade of Changes in Lung Cancer, with More to Come
Dr. Joan SchillerUsing data from SEER databases, Howlader and colleagues recently reported that incidence-based mortality from NSCLC in men decreased from 6.3% annually (95% CI, 3.4 to 9.0) from 2013 through 2016, in contrast to the period […] Read more
Stage IIIA NSCLC: A Review of Recent and Ongoing Trials
Mariano ProvencioTrial data can help inform change to standard of care, but at what point do we say enough data is enough and move forward with combination therapy as the new standard of care? Read more
Building and Maintaining a Patient–Physician Relationship in the COVID-19 Era
Robert Ramierz, DOAs oncologists, we recognize that the patient–physician relationship is of utmost importance in establishing the patient’s trust in the physician and in the physician’s ability to learn more about the patient’s needs and perform accurate assessments for […] Read more
Multidisciplinary Tumor Board: A Single Institution’s Perspective
Ari Rosenberg, MDAs 7:00 AM approaches, the ninth-floor conference room slowly fills as team members fi le in and find their seats. The senior radiation oncologist identifies his seat in the front row, carefully placing his stack […] Read more
Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic
Harpreet Singh, MDHarpreet Singh, MD, is director of Division of Oncology 2 at the U.S. Food and Drug Administration (FDA). In the following interview, she discusses the FDA’s response to the COVID-19 […] Read more